Lyra in Action

At Lyra, we are advancing leading-edge science to develop therapeutics that can make a positive impact on the lives of millions of patients.

Here are some of the ways we are making a difference for patients, for new therapeutic products, and for our community.

September 10, 2019
Lyra CEO Maria Palasis recognized as an industry leader

Our CEO Maria Palasis discusses connecting technology innovation with patient needs and shares advice for anyone pursuing a career in biotechnology in this interview in The Medicine Maker

September 10, 2019
Lyra Therapeutics hires CFO as the company’s lead medical treatment inches closer to commercialization

We are pleased to welcome our new CFO, R. Don Elsey, profiled in this WSJ.com CFO Journal article, to help Lyra develop into a commercially focused company as our lead drug candidate, LYR-210, enters a Phase 2 clinical trial for the treatment of chronic rhinosinusitis.

April 2019
Phase 1 results for LYR-210 featured in an editorial by a rhinology medical expert.

International Forum of Allergy & Rhinology, April 2019
Editorial by David W. Kennedy, M.D.

Douglas et al. report on a phase 1 clinical study of a novel biodegradable mometasone furoate drug delivery system for treating CRS in the unoperated patient. This is the first steroid-eluting implant intended for use in patients who have not had prior surgery, and elutes the steroid over a 24-week period.

March 8, 2019
Lyra recognizes diverse leadership on International Women’s Day

Lyra supports a diverse workplace and celebrates the company’s women executives and managers on International Women’s Day. We are proud to have our CEO Maria Palasis as a frequent speaker on the topic of women in science and industry.

March 2019
Global teamwork for International Forum of Allergy & Rhinology publication

Working with a team of researchers with global expertise, Lyra and Richard Douglas, M.D., Professor of Surgery at The University of Auckland, New Zealand, and Consultant Surgeon at Auckland City Hospital, publish Phase 1 clinical data for the company’s lead therapeutic, LYR210, for chronic rhinosinusitis (CRS), in the International Forum of Allergy & Rhinology [Publication]

Back to Top